These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 27793650)

  • 1. Interleukin 10 gene single nucleotide polymorphisms in Polish patients with chronic hepatitis C: Analysis of association with severity of disease and treatment outcome.
    Świątek-Kościelna B; Kałużna E; Strauss E; Januszkiewicz-Lewandowska D; Bereszyńska I; Wysocki J; Rembowska J; Barcińska D; Antosik D; Mozer-Lisewska I; Nowak J
    Hum Immunol; 2017 Feb; 78(2):192-200. PubMed ID: 27793650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients.
    Chuang JY; Yang SS; Lu YT; Hsieh YY; Chen CY; Chang SC; Chang CS; Yeh HZ; Kao JH
    Dig Liver Dis; 2009 Jun; 41(6):424-30. PubMed ID: 19004675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin.
    Abdelraheem WM; Hassuna NA; Abuloyoun SM; Abdel Ghany HM; Rizk HA; Abdelwahab SF
    Arch Virol; 2016 Sep; 161(9):2473-80. PubMed ID: 27352267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of IL10 Gene polymorphisms on the sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy.
    Guo P; Li G; Sun X; Wu D
    Infect Genet Evol; 2016 Nov; 45():48-55. PubMed ID: 27543394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secreted Phosphoprotein 1 Promoter Genetic Variants Are Associated with the Response to Pegylated Interferon α Plus Ribavirin Combination Therapy in Egyptian Patients with Chronic Hepatitis C Virus Infection.
    Ali FT; Ali MA; Elgizawy MM; Elsawy AM
    Gut Liver; 2015 Jul; 9(4):516-24. PubMed ID: 25717047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of interleukin-10 gene promoter polymorphisms -1082 G/A and -592 C/A on response to therapy in children and adolescents with chronic hepatitis C virus infection.
    El-Karaksy HM; Sharaf SA; Mandour IA; Mogahed EA; Rady NH; El-Mougy FA
    Hum Immunol; 2016 Dec; 77(12):1248-1253. PubMed ID: 27660094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-nucleotide polymorphism of Toll-like receptor 4 and interleukin-10 in response to interferon-based therapy in Egyptian chronic hepatitis C patients.
    Sadik NA; Shaker OG; Ghanem HZ; Hassan HA; Abdel-Hamid AH
    Arch Virol; 2015 Sep; 160(9):2181-95. PubMed ID: 26095186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese.
    Lim YP; Peng CY; Liao WL; Hung DZ; Tien N; Chen CY; Chang SY; Chang CY; Tsai FJ; Wan L
    J Med Virol; 2013 Jul; 85(7):1206-14. PubMed ID: 23918539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.
    Ishizu Y; Katano Y; Honda T; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
    J Gastroenterol Hepatol; 2012 Jun; 27(6):1112-6. PubMed ID: 22098610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.
    Naga M; Amin M; Algendy D; Elbadry A; Fawzi M; Foda A; Esmat S; Sabry D; Rashed L; Gabal S; Kamal M
    World J Gastroenterol; 2015 Oct; 21(39):11141-51. PubMed ID: 26494968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
    Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
    Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
    Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
    Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection.
    Morello J; Cuenca L; Soriano V; Medrano J; Madejón A; Vispo E; Barreiro P; Labarga P; Jiménez-Nácher I; Rodríguez-Nóvoa S
    J Infect Dis; 2010 Oct; 202(8):1185-91. PubMed ID: 20812847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
    Sikorska K; Stalke P; Izycka-Swieszewska E; Romanowski T; Bielawski KP
    Med Sci Monit; 2010 Mar; 16(3):CR137-143. PubMed ID: 20190684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E; Pisaturo M; Stanzione M; Messina V; Alessio L; Sagnelli C; Starace M; Pasquale G; Coppola N
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients.
    Dai CY; Chuang WL; Hsieh MY; Huang JF; Lin YY; Chu PY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antiviral Res; 2010 Feb; 85(2):396-402. PubMed ID: 19931565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.
    Kohjima M; Yoshimoto T; Enjoji M; Fukushima N; Fukuizumi K; Nakamura T; Kurokawa M; Fujimori N; Sasaki Y; Shimonaka Y; Murata Y; Koyama S; Kawabe K; Haraguchi K; Sumida Y; Harada N; Kato M; Kotoh K; Nakamuta M
    World J Gastroenterol; 2015 Mar; 21(11):3291-9. PubMed ID: 25805936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.
    Nattermann J; Vogel M; Berg T; Danta M; Axel B; Mayr C; Bruno R; Tural C; Klausen G; Clotet B; Lutz T; Grünhage F; Rausch M; Nischalke HD; Schewe K; Bienek B; Haerter G; Sauerbruch T; Rockstroh JK; Spengler U;
    Hepatology; 2007 Oct; 46(4):1016-25. PubMed ID: 17668881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction effects among IFN-γ+874, IL-2-330, IL-10-1082, IL-10-592 and IL-4-589 polymorphisms on the clinical progression of subjects infected with hepatitis B virus and/or hepatitis C virus: a retrospective nested case-control study.
    Gao QJ; Xie JX; Wang LM; Zhou Q; Zhang SY
    BMJ Open; 2017 Aug; 7(8):e013279. PubMed ID: 28838891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.